Inhibrx Biosciences, Inc.
INBXNASDAQHealthcare● Active
$87.94
+$0.93(+1.06%)
Market Cap$1.3B
P/E Ratio—
52W High$155.29
52W Low$12.8
Inhibrx Biosciences, Inc. (INBX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · INBX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.30M | $0.20M | $1.80M | $2.19M | $7.13M |
| Cost of Revenue | $2.48M | $2.29M | $1.19M | $110.19M | $2.69M |
| Gross Profit | ($1.18M) | ($2.08M) | $0.61M | ($107.99M) | $4.44M |
| Gross Margin %(computed) | -91.00% | — | 33.83% | — | 62.27% |
| Operating Expenses | |||||
| R&D Expenses | $113.03M | $203.74M | $190.65M | $110.19M | $71.44M |
| G&A Expenses | $23.30M | $127.91M | $29.38M | $21.12M | $12.36M |
| Total Operating Expenses | $133.84M | $329.36M | $219.83M | $21.12M | $12.34M |
| Operating Income | ($135.03M) | ($331.45M) | ($219.22M) | ($129.12M) | ($76.56M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $7.55M | $10.94M | $11.92M | $16.11M | $5.22M |
| Interest Expense | $12.20M | $13.49M | $31.84M | $16.11M | $5.22M |
| Income Before Tax | ($140.05M) | $1687.57M | ($239.72M) | ($145.22M) | ($81.77M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($140.06M) | $1687.57M | ($241.36M) | ($145.23M) | ($81.77M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-9.04 | $116.58 | $-5.12 | $-3.62 | $-2.15 |
| Wtd Avg Shares | 15.49M | 14.48M | 47.13M | 40.11M | 38.01M |
| EBITDA | ($132.54M) | $1703.35M | ($206.69M) | ($125.82M) | ($75.37M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Inhibrx Biosciences, Inc. data
About Inhibrx Biosciences, Inc. (INBX) Income Statement
Inhibrx Biosciences, Inc. (INBX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, INBX reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -91.00%), and net income of ($0.14B) — a net profit margin of -10773.46%.
Frequently asked questions
INBX · 4 questionsInhibrx Biosciences, Inc. (INBX) reported revenue of $0.00B for 2025, up 550.0% year-over-year.
INBX revenueINBX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08